Company Overview
Septerna is a biotechnology company focused on G protein-coupled receptor targeted medicines. The company develops small molecule programmes against GPCR targets, a receptor family that has historically been difficult to drug.
Recent Leadership News
Amer Mirza, Vice President of Disease Biology and Translational Sciences, was appointed Chief Scientific Officer at Prolynx in July 2026.
Facts compiled by Executive Moves from publicly available news and press releases on 17 July 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you on the Septerna team?
This is a Light company page, auto-generated from public news coverage. Claim it to verify the company description, add logo and links, and control how your organisation is represented on Executive Moves.
Claim this company →
